6-fluoro-L-DOPA
Commercial- Indications
- Neuroendocrine tumors, Parkinson's disease
Company intelligence / Profile preview
ITEL has a long-standing track record in developing advanced shielding solutions for MRI/PET/CT installations worldwide. Its Itelpharma division produces GMP-certified PET tracers and other radiopharmaceuticals. The company’s spin-off LinearBeam has developed the ERHA linear accelerator-based proton therapy system targeting cancer treatment. Clinical results are not detailed publicly but the company’s technologies are deployed internationally across healthcare institutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ITEL Telecomunicazioni.